Zing Health
Private Equity Round in 2024
Zing Health is a tech-enabled insurance company focused on providing Medicare Advantage plans tailored for individuals aged 65 and over. With a community-based approach, Zing Health emphasizes the significance of social determinants of health in promoting wellness among its members. The company aims to place both physicians and members at the forefront of the healthcare experience, facilitating a more personalized and supportive environment. Zing Health offers individualized assistance to ensure a smooth transition for new members, along with the opportunity to customize their healthcare plans. Additionally, members have access to facilities designed to address their specific healthcare needs and benefit from a dedicated care team that supports their health management. By targeting historically underserved populations, Zing Health strives to reduce healthcare disparities and enhance the overall health outcomes of its members.
T2 Biosystems
Post in 2024
T2 Biosystems, Inc. is an in vitro diagnostics company focused on developing advanced diagnostic products for detecting pathogens and biomarkers. Utilizing its proprietary T2 Magnetic Resonance technology, the company offers rapid and accurate testing for various medical conditions directly from unpurified patient samples, including whole blood, plasma, and urine. Key products include the T2Dx Instrument for diagnosing sepsis and Lyme disease, the T2Candida Panel for identifying Candida species, and the T2Bacteria Panel for detecting bacterial pathogens linked to sepsis. Additionally, T2 Biosystems provides the T2Resistance Panel for identifying antibiotic resistance markers and is developing other diagnostic panels for multi-drug resistant pathogens and Lyme disease strains. The company collaborates with organizations like Canon U.S. Life Sciences and Allergan Sales to enhance its testing capabilities. Founded in 2006 and based in Lexington, Massachusetts, T2 Biosystems aims to improve patient care and reduce healthcare costs through its innovative diagnostic solutions.
Calyxo, Inc. is a medical device company established in 2016 that specializes in innovative solutions for patients suffering from kidney stones, a condition that significantly impacts healthcare resources. The company has developed a vacuum-assisted retrieval device that allows for the efficient removal of multiple kidney stone fragments in a single insertion, offering a quick and effective procedure for healthcare providers. This device aims to enhance patient outcomes by ensuring a stone-free result, thereby streamlining the treatment process. Calyxo is led by a team of experienced professionals with a strong background in urology, united by a commitment to improving kidney stone care through technological advancements.
NavaDerm Partners
Debt Financing in 2021
NavaDerm Partners, LLC is a healthcare management company specializing in dermatology services, encompassing medical, surgical, and cosmetic procedures. Founded in 2018, it operates several centers in New York and New Jersey, providing a range of treatments including acne management, skin cancer care, and cosmetic enhancements such as laser treatments and body contouring. NavaDerm Partners supports a network of over 40 board-certified dermatologists and their teams, facilitating high-quality patient care across its eight locations. The company also offers practice management services, including accounting, human resources, and IT support, allowing clinicians to concentrate on delivering exceptional medical care while enhancing their practice's reputation and patient referrals.
Treace Medical Concepts
Debt Financing in 2020
Treace Medical Concepts, Inc. is a medical device company based in Ponte Vedra Beach, Florida, that specializes in the design, manufacture, and marketing of innovative surgical solutions for foot and ankle physicians. Founded in 2014, the company focuses on advancing the standard of care for bunion deformities through its patented Lapiplasty 3D Bunion Correction procedure. This procedure aims to correct all planes of the bunion deformity effectively, addressing its root cause and facilitating quicker recovery for patients. Additionally, Treace Medical Concepts offers the ProHarvester, a percutaneous autograft extraction system that allows for minimally invasive harvesting of autograft bone and bone marrow. The company operates within the expanding $1.1 billion U.S. market for foot and ankle surgical products, with a commitment to improving patient outcomes and reducing healthcare costs.
Aerin Medical
Debt Financing in 2019
Aerin Medical Inc. is a health technology company based in Sunnyvale, California, specializing in non-invasive treatment solutions for nasal breathing disorders. Established in 2011, the company has developed therapeutic devices that utilize low-power radiofrequency energy to remodel nasal soft tissues, effectively addressing the underlying causes of nasal congestion. Its primary products include the VivAer procedure for nasal airway obstruction and the RhinAer procedure for chronic rhinitis, both of which employ proprietary temperature-controlled technology. These solutions offer ENT physicians appealing alternatives to invasive surgery, allowing them to treat patients under local anesthesia with minimal to no downtime. Aerin Medical aims to meet the unmet needs of individuals suffering from chronic nasal airway conditions through its innovative and office-friendly product offerings.
Harmony Biosciences
Debt Financing in 2019
Harmony Biosciences is a commercial-stage pharmaceutical company based in Plymouth Meeting, Pennsylvania, founded in 2017. The company is dedicated to developing and commercializing innovative therapies for patients with rare neurological disorders who have unmet medical needs. Its primary product, WAKIX (pitolisant), is designed to treat narcolepsy in pediatric patients and has a unique mechanism of action that enhances histamine signaling in the brain by binding to H3 receptors. Harmony Biosciences aims to address critical therapeutic gaps in the treatment of neurological conditions, focusing on improving the quality of life for affected individuals.
EyePoint Pharmaceuticals
Debt Financing in 2019
EyePoint Pharmaceuticals, Inc. is a specialty biopharmaceutical company focused on developing and commercializing ophthalmic products for the treatment of eye diseases in the United States and Europe. The company offers several FDA-approved products, including ILUVIEN for diabetic macular edema, YUTIQ for chronic non-infectious uveitis, DEXYCU for post-operative ocular inflammation, and Retisert for posterior segment uveitis. Additionally, EyePoint is advancing its pipeline with innovative therapies such as EYP-1901, targeting wet age-related macular degeneration and diabetic retinopathy, and YUTIQ50 for uveitis. The company employs its proprietary Durasert and Verisome technology platforms to create sustained-release drug delivery systems that provide controlled drug delivery over extended periods. EyePoint has established strategic collaborations with various organizations to enhance its product offerings and has a commercial alliance for the joint promotion of DEXYCU. Founded in 1987 and headquartered in Watertown, Massachusetts, EyePoint was formerly known as pSivida Corp. and rebranded in March 2018.
Mid-Atlantic Dental Partners
Venture Round in 2019
Mid-Atlantic Dental Partners is a regional dental support organization that focuses on enhancing the delivery of dental care. Founded on the principle of a collaborative partnership among patients, dentists, and support organizations, it aims to allow dental professionals to concentrate on patient care by managing non-clinical activities. These services encompass billing, collections, scheduling, clinical data analytics, group purchasing, marketing, and recruitment of dental staff. The organization is dedicated to maintaining clinical autonomy for dentists while improving the overall lifestyle of its dental partners and their teams.
HNI Healthcare
Private Equity Round in 2018
HNI Healthcare, previously known as Hospitalists Now, is a physician practice management company that leverages technology to enhance the delivery of facility-based physician services. The organization specializes in implementing full-service programs aimed at improving patient care quality through a clinically integrated care model. By focusing on value-based patient care, HNI Healthcare's platform assists hospitals and physicians in optimizing key quality and performance metrics, thereby promoting better health outcomes within healthcare facilities.
EndoGastric Solutions
Series I in 2018
EndoGastric Solutions, Inc. is a medical device company specializing in innovative surgical technologies aimed at treating gastrointestinal diseases, particularly gastroesophageal reflux disease (GERD). Founded in 2002 and headquartered in Redmond, Washington, with an additional office in San Mateo, California, the company develops and manufactures natural orifice surgical products. Its flagship technology, EsophyX, facilitates transoral reconstructive surgery, while the EsophyX Z device is specifically designed for the transoral incisionless fundoplication procedure. Additionally, EndoGastric Solutions offers SerosaFuse Fasteners, a non-resorbable polypropylene product that provides strength comparable to traditional sutures. The company also supports surgeons through training courses and a range of consultative services, including pre-authorization and medical review.
Fast Pace Health
Private Equity Round in 2018
Fast Pace Health provides primary and urgent care to the communities they serve. They provide treatments for minor injuries, skin conditions, and diagnostics. Their services include behavioral health, dermatology care, occupational health, physical therapy, orthopedic care, and telehealth services.
Dynavax Technologies
Post in 2018
Dynavax Technologies Corporation is a biopharmaceutical company specializing in the development and commercialization of innovative vaccines. Its flagship product, HEPLISAV-B, is a recombinant adjuvanted hepatitis B vaccine approved for use in adults aged 18 years and older, targeting all known subtypes of the hepatitis B virus. The company utilizes its proprietary Toll-like Receptor Immune Modulation Platform to enhance both innate and adaptive immune responses. Dynavax is actively advancing its immuno-oncology portfolio and has several development-stage products, including SD-101 and DV281, aimed at various cancer indications. In addition, the company engages in multiple research collaborations to develop adjuvanted vaccines for infectious diseases, including COVID-19, partnering with organizations such as Clover Biopharmaceuticals, the University of Queensland, and the Coalition for Epidemic Preparedness Innovations. Established in 1996 and headquartered in Emeryville, California, Dynavax continues to expand its role in vaccine development.
Synergy Pharmaceuticals
Post in 2017
Synergy Pharmaceuticals Inc., based in New York with laboratories in Doylestown, PA, is a biopharmaceutical company dedicated to the research and development of innovative therapies for gastrointestinal conditions. The company primarily focuses on chronic idiopathic constipation, irritable bowel syndrome with constipation, and other challenging GI disorders. Its leading product, plecanatide, is a once-daily tablet designed to treat chronic idiopathic constipation and irritable bowel syndrome. Additionally, Synergy is developing dolcanatide, which targets inflammatory bowel disease by enhancing digestive processes. Both plecanatide and dolcanatide are proprietary analogs of the natural human gastrointestinal hormone uroguanylin and belong to a new class of guanylate cyclase-C (GC-C) agonists, reflecting the company’s commitment to addressing unmet medical needs in the gastrointestinal space.
Silk Road Medical
Series C in 2017
Silk Road Medical, Inc. is a medical device company based in Sunnyvale, California, specializing in the treatment of carotid artery disease through its innovative transcarotid artery revascularization (TCAR) approach. Founded in 2007, the company develops and manufactures minimally invasive devices aimed at reducing the risk of stroke and improving patient outcomes. Its product portfolio includes the ENROUTE Transcarotid Neuroprotection System, which facilitates direct access to the common carotid artery while ensuring temporary blood flow reversal to protect the brain, and the ENROUTE Transcarotid Stent System, a self-expanding stent supported by clinical data on safety outcomes. Additionally, the ENHANCE Transcarotid Peripheral Access Kit and the ENROUTE 0.014 Guidewire are designed to aid in gaining access and delivering interventional devices effectively. Silk Road Medical aims to establish TCAR as the standard of care for carotid artery disease treatment.
Strongbridge Biopharma
Post in 2017
Strongbridge Biopharma plc is a commercial-stage biopharmaceutical company dedicated to developing and commercializing therapies for rare diseases with significant unmet medical needs. The company’s primary focus is on rare endocrine disorders, exemplified by its product candidates, Recorlev, a cortisol synthesis inhibitor currently in Phase III trials for endogenous Cushing's syndrome, and Veldoreotide, a somatostatin analog that has completed Phase II trials for acromegaly. Strongbridge also offers Keveyis, an oral carbonic anhydrase inhibitor approved for treating specific forms of periodic paralysis in the United States. Founded in 1996 and headquartered in Trevose, Pennsylvania, the company aims to leverage a concentrated prescriber base for its products and plans to utilize a targeted sales force for marketing in the U.S., European Union, and other key markets. Additionally, Strongbridge seeks to enhance its portfolio through the in-licensing or acquisition of complementary products that align with its focus on rare endocrine conditions.
Strongbridge Biopharma
Post in 2017
Strongbridge Biopharma plc is a commercial-stage biopharmaceutical company dedicated to developing and commercializing therapies for rare diseases with significant unmet medical needs. The company’s primary focus is on rare endocrine disorders, exemplified by its product candidates, Recorlev, a cortisol synthesis inhibitor currently in Phase III trials for endogenous Cushing's syndrome, and Veldoreotide, a somatostatin analog that has completed Phase II trials for acromegaly. Strongbridge also offers Keveyis, an oral carbonic anhydrase inhibitor approved for treating specific forms of periodic paralysis in the United States. Founded in 1996 and headquartered in Trevose, Pennsylvania, the company aims to leverage a concentrated prescriber base for its products and plans to utilize a targeted sales force for marketing in the U.S., European Union, and other key markets. Additionally, Strongbridge seeks to enhance its portfolio through the in-licensing or acquisition of complementary products that align with its focus on rare endocrine conditions.
EarLens
Debt Financing in 2017
Earlens is a medical technology company focused on improving the hearing experience for individuals with hearing loss. It has created the Earlens Contact Hearing Solution, a unique device that directly stimulates the eardrum using a small lens, replicating the natural hearing process. Unlike conventional hearing aids that amplify sound, the Earlens solution delivers sound directly to the eardrum, providing superior sound quality and a broader bandwidth. This innovative, non-surgical approach allows for automatic adjustments in challenging listening environments while minimizing feedback. The technology received FDA clearance in 2019 for its second generation, marking a significant advancement in hearing solutions aimed at enhancing the quality of life for those with hearing impairment.
Earlens is a medical technology company focused on improving the hearing experience for individuals with hearing loss. It has created the Earlens Contact Hearing Solution, a unique device that directly stimulates the eardrum using a small lens, replicating the natural hearing process. Unlike conventional hearing aids that amplify sound, the Earlens solution delivers sound directly to the eardrum, providing superior sound quality and a broader bandwidth. This innovative, non-surgical approach allows for automatic adjustments in challenging listening environments while minimizing feedback. The technology received FDA clearance in 2019 for its second generation, marking a significant advancement in hearing solutions aimed at enhancing the quality of life for those with hearing impairment.
Viveve
Debt Financing in 2017
Viveve is a women's sexual health company that specializes in non-surgical treatments aimed at addressing issues related to vaginal looseness and loss of sensation, which can occur after childbirth. The company has developed the Viveve System, a medical technology that employs cryogen-cooled monopolar radiofrequency technology to restore collagen fibers that may have been overstretched or damaged during delivery. This system is designed for non-invasive treatments of vaginal laxity, sexual function enhancement, vaginal rejuvenation, and stress urinary incontinence. Founded in 2005 and based in Palo Alto, California, Viveve operates in multiple regions, including the United States, Asia Pacific, Canada, Europe, the Middle East, and Latin America, and markets its products for various surgical applications.
BioDelivery Sciences International
Post in 2017
BioDelivery Sciences International, Inc. is a specialty pharmaceutical company focused on developing and commercializing products for pain management and addiction medicine. Headquartered in Raleigh, North Carolina, the company utilizes its proprietary BioErodible MucoAdhesive (BEMA) drug delivery technology, which features a small erodible polymer film designed for application to the buccal mucosa. Its product offerings include BELBUCA, a buprenorphine buccal film for chronic pain; BUNAVAIL, a buprenorphine and naloxone buccal film for opioid dependence; ONSOLIS, a fentanyl buccal soluble film for breakthrough cancer pain; and Symproic, which addresses opioid-induced constipation in adult patients with chronic non-cancer pain. Founded in 1997, BioDelivery Sciences is committed to addressing significant unmet medical needs through innovative therapeutic solutions.
Endoceutics
Debt Financing in 2017
Endoceutics is a biopharmaceutical company focused on women's health, particularly in the areas of hormone-sensitive cancer prevention and treatment. The company specializes in developing hormone therapies aimed at addressing breast cancer and endocrine-related disorders. Endoceutics is engaged in the clinical development, recording, and marketing of its products, which are at various stages of development. Its mission is to enhance the quality of life for women by advancing basic sciences, conducting clinical research, and commercializing effective treatments for menopausal issues and related health concerns.
Barricaid
Venture Round in 2016
Barricaid is a medical device company that focuses on developing innovative solutions to prevent repeat disc herniation in patients who have undergone back surgery. The company's flagship product is a bone-anchored implant designed to reduce the likelihood of reherniation and the need for reoperation in cases involving large annular defects. This implant physically blocks the annulus at the surgical defect, enhancing the surgical outcome for patients at high risk of complications after lumbar discectomy. Composed of a titanium alloy, the device securely anchors into the vertebral body, either caudally or cranially, ensuring stability and effectiveness. By addressing the challenges associated with post-surgical recovery, Barricaid aims to improve patient outcomes and reduce the incidence of further surgeries related to sciatica.
Hicuity Health
Debt Financing in 2016
Hicuity Health is a leading provider of high acuity telehealth services, delivering care to over 115 hospitals across 30 states on a continuous basis. The company focuses on acute care telemedicine, offering ICU programs and evidence-based protocols that utilize advanced telehealth technology. By connecting U.S. board-certified intensivists, nurses, and onsite clinicians with patients and their families, Hicuity Health enhances critical care delivery. The organization operates multiple dedicated tele-care delivery centers and emphasizes a proven implementation and client service approach, ultimately aiming to improve patient outcomes and support healthcare providers and institutions.
T2 Biosystems
Post in 2016
T2 Biosystems, Inc. is an in vitro diagnostics company focused on developing advanced diagnostic products for detecting pathogens and biomarkers. Utilizing its proprietary T2 Magnetic Resonance technology, the company offers rapid and accurate testing for various medical conditions directly from unpurified patient samples, including whole blood, plasma, and urine. Key products include the T2Dx Instrument for diagnosing sepsis and Lyme disease, the T2Candida Panel for identifying Candida species, and the T2Bacteria Panel for detecting bacterial pathogens linked to sepsis. Additionally, T2 Biosystems provides the T2Resistance Panel for identifying antibiotic resistance markers and is developing other diagnostic panels for multi-drug resistant pathogens and Lyme disease strains. The company collaborates with organizations like Canon U.S. Life Sciences and Allergan Sales to enhance its testing capabilities. Founded in 2006 and based in Lexington, Massachusetts, T2 Biosystems aims to improve patient care and reduce healthcare costs through its innovative diagnostic solutions.
Omeros Corporation is a Seattle-based biopharmaceutical company that focuses on discovering, developing, and commercializing small-molecule and protein therapeutics targeting inflammation, complement-mediated diseases, and disorders of the central nervous system. The company offers OMIDRIA, a product used during cataract surgery in the United States. Omeros is advancing several clinical programs, including narsoplimab, which is in Phase III trials for conditions such as hematopoietic stem-cell transplant-associated thrombotic microangiopathy and immunoglobulin A nephropathy, as well as Phase II trials for lupus nephritis. Other key programs include OMS405, targeting opioid and nicotine addiction, and OMS527, aimed at treating addiction and movement disorders. The company's preclinical pipeline includes compounds addressing various conditions, such as paroxysmal nocturnal hemoglobinuria and other alternative pathway disorders. Founded in 1994, Omeros is dedicated to addressing both large-market and orphan indications through innovative therapeutic approaches.
Access TeleCare
Debt Financing in 2016
Access TeleCare is a provider of acute care telemedicine services designed for hospitals, health systems, post-acute providers, and physician networks. The company specializes in a range of telehealth services, including telecardiology, teleneurology, telepsychiatry, telepulmonology, telehospitalists, teleinfectious disease, and telematernal fetal medicine. By leveraging advanced technology, Access TeleCare facilitates virtual patient care, allowing healthcare organizations to develop and sustain telemedicine programs across various clinical specialties. The company's model supports healthcare providers in enhancing patient access to specialized care while maintaining quality and efficiency in service delivery.
US WorldMeds
Venture Round in 2016
US WorldMeds is a specialty pharmaceutical company based in Kentucky, focused on developing, licensing, and commercializing unique pharmaceuticals that address unmet medical needs. Founded in 2001 by CEO Paul Breckinridge "Breck" Jones, the company aims to create innovative treatments primarily for conditions such as Parkinson's disease, cervical dystonia, malignant hyperthermia, and other rare diseases. By leveraging local talent and expertise, US WorldMeds aspires to be a significant player in the pharmaceutical industry while maintaining its closely-held structure. The company is dedicated to improving the lives of patients and is committed to expanding its presence as a responsible corporate citizen, fostering innovation, and creating high-quality jobs in its headquarters in Louisville and its satellite offices and manufacturing facilities.
Iroko Pharmaceuticals
Debt Financing in 2016
Iroko Pharmaceuticals, LLC is a specialty pharmaceutical company based in Philadelphia, Pennsylvania, focused on developing and commercializing innovative pharmaceutical products for pain management. Founded in 2007, the company markets a range of prescription pain medications, including Indocid, Aldomet, TIVORBEX, ZORVOLEX, and VIVLODEX, which are designed to address various pain management needs, particularly for patients with osteoarthritis and acute pain. Iroko utilizes proprietary technology to formulate lower-dose nonsteroidal anti-inflammatory drugs (NSAIDs), improving therapeutic options for patients. The company has established a robust distribution and sales network, extending its reach to more than 40 countries, and aims to enhance healthcare by revitalizing existing medications through new applications and geographic markets.
Cardiome Pharma
Post in 2016
Cardiome Pharma Corp. is a specialty biopharmaceutical company dedicated to the discovery, development and commercialization of new therapies that will improve the health of patients suffering from heart disease around the world. Cardiome has one marketed product, BRINAVESSTM (vernakalant IV), approved in Europe and other territories for the rapid conversion of recent onset atrial fibrillation to sinus rhythm in adults.
Valeritas Holdings
Venture Round in 2016
Valeritas Holdings, Inc. was a medical technology company focused on developing and commercializing innovative solutions for the treatment of Type 2 diabetes. Founded in 2006 and headquartered in Bridgewater, New Jersey, the company offered the V-Go, a wearable insulin delivery device designed for basal-bolus therapy, allowing patients to manage their insulin intake conveniently and discreetly. Valeritas was also working on additional products, including the V-Go Prefill, aimed at simplifying the device-filling process, and V-Go SIM, which would facilitate real-time tracking of dosing utilization. The company marketed its products through third-party wholesalers and medical supply distributors, aiming to enhance the health and quality of life for individuals living with diabetes. However, on June 30, 2020, Valeritas Holdings filed for Chapter 11 bankruptcy, leading to its cessation of operations.
Benvenue Medical
Debt Financing in 2016
Benvenue Medical, Inc. is a company specializing in the design, manufacture, and marketing of minimally invasive expandable implant systems for the treatment of spinal disorders, particularly vertebral compression fractures and degenerative disc diseases. Its key products include the Kiva treatment system, which addresses spinal fractures in the thoracic and lumbar regions, and the Blazer – C system, designed for pathological vertebral compression fractures. Additionally, the company offers the Luna 3D expandable interbody fusion system, suitable for various surgical approaches. Headquartered in Santa Clara, California, Benvenue Medical serves customers across the United States, Canada, Belgium, France, and Germany. Founded in 2004, the company is committed to providing innovative solutions that enhance patient outcomes and restore spinal alignment.
Realeve
Debt Financing in 2016
Autonomic Technologies, Inc. is a medical device company that specializes in developing and commercializing innovative therapies for autonomic disorders, with a particular emphasis on severe headaches. Founded in 2007 and headquartered in Mountain View, California, the company has additional offices in Germany and Switzerland. Its flagship product, the ATI Neurostimulation System, is a miniaturized, battery-less microstimulator designed to deliver low-level energy directly to the sphenopalatine ganglion (SPG) to effectively treat chronic cluster headaches. This technology aims to set a new standard in the management of severe headaches and migraines, providing patients with a safe and effective treatment option.
EndoGastric Solutions
Venture Round in 2015
EndoGastric Solutions, Inc. is a medical device company specializing in innovative surgical technologies aimed at treating gastrointestinal diseases, particularly gastroesophageal reflux disease (GERD). Founded in 2002 and headquartered in Redmond, Washington, with an additional office in San Mateo, California, the company develops and manufactures natural orifice surgical products. Its flagship technology, EsophyX, facilitates transoral reconstructive surgery, while the EsophyX Z device is specifically designed for the transoral incisionless fundoplication procedure. Additionally, EndoGastric Solutions offers SerosaFuse Fasteners, a non-resorbable polypropylene product that provides strength comparable to traditional sutures. The company also supports surgeons through training courses and a range of consultative services, including pre-authorization and medical review.
Silk Road Medical
Venture Round in 2015
Silk Road Medical, Inc. is a medical device company based in Sunnyvale, California, specializing in the treatment of carotid artery disease through its innovative transcarotid artery revascularization (TCAR) approach. Founded in 2007, the company develops and manufactures minimally invasive devices aimed at reducing the risk of stroke and improving patient outcomes. Its product portfolio includes the ENROUTE Transcarotid Neuroprotection System, which facilitates direct access to the common carotid artery while ensuring temporary blood flow reversal to protect the brain, and the ENROUTE Transcarotid Stent System, a self-expanding stent supported by clinical data on safety outcomes. Additionally, the ENHANCE Transcarotid Peripheral Access Kit and the ENROUTE 0.014 Guidewire are designed to aid in gaining access and delivering interventional devices effectively. Silk Road Medical aims to establish TCAR as the standard of care for carotid artery disease treatment.
GenomeDx Biosciences
Debt Financing in 2015
GenomeDx discovers, develops, and commercializes genomic-based laboratory tests for the personalized medicine revolution in cancer care. In partnership with physicians and scientists from leading academic medicine institutions, our mission is to bring cost-effective and high-resolution genomics for routine clinical use in cancer medicine.
Avinger, Inc. is a medical device company focused on developing catheter-based technologies for the treatment of peripheral arterial disease (PAD). Founded in 2007 and headquartered in Redwood City, California, Avinger designs and manufactures image-guided systems that assist physicians in managing vascular diseases. Its product lineup includes the Lightbox imaging console and the Ocelot family of catheters, which facilitate penetration of total blockages in arteries, known as chronic total occlusions (CTOs). Additionally, the Pantheris device offers image-guided atherectomy, enabling precise removal of arterial plaque in PAD patients. Avinger markets its products to interventional cardiologists, vascular surgeons, and interventional radiologists across the United States and Europe.
ViewRay, Inc. is a company that designs, manufactures, and markets advanced radiation therapy systems for cancer treatment. Its primary product, MRIdian, is an MRI-guided radiation therapy system that allows for simultaneous imaging and treatment of cancer patients. This innovative system integrates MRI technology, radiation delivery, and proprietary software to accurately locate and track soft-tissue tumors, enabling precise targeting while minimizing radiation exposure to surrounding healthy tissues. By providing real-time imaging during treatment, MRIdian addresses significant limitations of traditional radiation therapy methods, enhancing the safety and effectiveness of cancer treatment. ViewRay serves a diverse clientele, including university hospitals, community hospitals, private practices, government institutions, and independent cancer centers, primarily in the United States and internationally. The company was founded in 2004 and is headquartered in Oakwood, Ohio.
Outset Medical
Debt Financing in 2015
Outset Medical, Inc. is a medical technology company based in San Jose, California, focused on innovating hemodialysis systems. The company has developed Tablo, a compact dialysis machine designed for use in both acute and chronic care settings. This system integrates essential features such as water purification, on-demand dialysate production, and advanced software capabilities, including wireless data connectivity and sensor-based automation. By simplifying the dialysis process, Tablo aims to reduce costs and enhance the experience for both patients and healthcare providers. Founded in 2003 and originally named Home Dialysis Plus, Ltd., Outset Medical rebranded in 2015 to reflect its commitment to transforming dialysis care.
Navidea Biopharmaceuticals
Post in 2015
Navidea Biopharmaceuticals, Inc. is a biopharmaceutical company dedicated to the development and commercialization of precision immunodiagnostic agents and immunotherapeutics. The company operates through two main segments: Diagnostic Substances and Therapeutic Development Programs. Central to its efforts is the Manocept platform, which targets the CD206 mannose receptor found on activated macrophages, enabling innovative approaches to diagnostic imaging and therapeutic delivery. This platform supports a variety of diagnostic modalities, including PET imaging, and is designed to address immune and inflammation-related diseases. Notably, Navidea offers NAV4694, a PET imaging agent for assessing Alzheimer’s disease and mild cognitive impairment. Additionally, the company is advancing other diagnostic substances and therapeutic programs, with a collaboration agreement in place with IMV Inc. to explore combined immunotherapeutic effects. Founded in 1983 and headquartered in Dublin, Ohio, Navidea Biopharmaceuticals previously operated under the name Neoprobe Corporation until 2012.
Ceterix Orthopaedics
Debt Financing in 2015
Ceterix Orthopaedics, Inc. is a medical technology company focused on developing innovative surgical tools for arthroscopic procedures. Based in Fremont, California, the company offers the Ceterix NovoStitch® Plus Meniscal Repair System, designed to repair various complex meniscal tears, including horizontal, radial, and root tears. Additionally, Ceterix provides the Novocut Suture Manager, a device that facilitates suture management during surgeries. The company's technology allows orthopedic surgeons to non-invasively create intricate suture patterns in tight joint compartments while safeguarding surrounding structures such as nerves and cartilage. Founded in 2010 by Dr. Justin Saliman, an orthopedic surgeon specializing in sports medicine, Ceterix aims to enhance the outcomes of arthroscopic procedures, addressing issues that often lead to untreated tears or the more invasive meniscectomy. As of January 2019, Ceterix operates as a subsidiary of Smith & Nephew plc.
TearLab Corporation is an in-vitro diagnostic company based in Escondido, California, specializing in the development of lab-on-a-chip technologies for eye care. The company's flagship product, the TearLab Osmolarity System, is a proprietary platform designed for the diagnosis of dry eye disease by measuring tear film osmolarity. This system enables eye care practitioners to test for specific biomarkers using minimal tear samples at the point-of-care. The TearLab Osmolarity System includes a disposable microfluidic microchip, a hand-held device called the TearLab Pen, and a desktop unit, the TearLab Reader, which provides quantitative readings. Established in 1996, TearLab was formerly known as OccuLogix, Inc., and as of July 2020, it has transitioned to a private company.
Imaging Advantage
Private Equity Round in 2015
Imaging Advantage is a prominent provider of technology-enhanced radiology solutions that focus on evidence-based practices for hospitals throughout the United States. The company offers innovative cloud-based technology designed to improve provider utilization and operational efficiency by integrating various information technology systems. Through the use of clinical and business algorithms, Imaging Advantage helps healthcare organizations optimize resource allocation, ensuring a better match between supply and demand within their networks. Its services are utilized by major healthcare systems in states including Arizona, California, Illinois, Michigan, Ohio, Oregon, and Texas, as well as in other significant metropolitan areas across the country.
Imaging Advantage
Debt Financing in 2015
Imaging Advantage is a prominent provider of technology-enhanced radiology solutions that focus on evidence-based practices for hospitals throughout the United States. The company offers innovative cloud-based technology designed to improve provider utilization and operational efficiency by integrating various information technology systems. Through the use of clinical and business algorithms, Imaging Advantage helps healthcare organizations optimize resource allocation, ensuring a better match between supply and demand within their networks. Its services are utilized by major healthcare systems in states including Arizona, California, Illinois, Michigan, Ohio, Oregon, and Texas, as well as in other significant metropolitan areas across the country.
Blue Belt Technologies
Debt Financing in 2014
Blue Belt Technologies, Inc. focuses on the development and commercialization of robotics-assisted technologies designed for orthopedic surgery and other medical specialties. The company offers the Navio surgical system, which integrates intelligent handheld instruments with a CT-free registration and patient-specific planning process. Additionally, it provides the STRIDE unicondylar knee system for treating early-stage osteoarthritis in the knee, along with software applications that assist surgeons in planning knee replacements. These applications help in localizing implant components and balancing soft tissue. Beyond product offerings, Blue Belt Technologies also delivers support services, maintenance programs, and onsite training. Founded in 2003 and headquartered in Plymouth, Minnesota, Blue Belt Technologies became a subsidiary of Smith & Nephew in January 2016.
Astute Medical
Debt Financing in 2014
Astute Medical, Inc. is a life science tools company specializing in the discovery and development of protein biomarkers for rapid diagnosis and risk assessment of acute medical conditions. Founded in 2007 and based in San Diego, California, with a location in Paris, France, the company focuses on validating prognostic biomarkers related to conditions such as abdominal pain, acute coronary syndromes, cerebrovascular injury, kidney injury, and sepsis. Its primary product, NephroCheck, is a single-use cartridge designed to detect biomarkers of acute kidney injury, while the Astute140 meter converts the fluorescent signals from the NephroCheck cartridge into a single numerical result. Astute Medical's products are marketed in the United States and Europe and aim to enhance clinical decision-making and patient outcomes. As of April 2018, Astute Medical operates as a subsidiary of bioMérieux S.A.
Nevro
Debt Financing in 2014
Nevro Corporation is a global medical device company specializing in innovative solutions for chronic pain management. Its primary product is the Senza spinal cord stimulation (SCS) system, which employs proprietary HF10 therapy to deliver evidence-based neuromodulation treatment. The Senza system consists of implantable components controlled by patients and managed by healthcare professionals using specialized software. Nevro generates a significant portion of its revenue in the United States.
Exagen
Debt Financing in 2014
Exagen Inc. is a diagnostics company focused on improving the care of patients with autoimmune diseases through the development and commercialization of innovative testing products under its AVISE brand. Utilizing its proprietary Cell-Bound Complement Activation Products technology, Exagen offers a range of tests aimed at the diagnosis, prognosis, and monitoring of complex autoimmune and autoimmune-related disorders, such as systemic lupus erythematosus and rheumatoid arthritis. Among its key products are AVISE CTD, which supports differential diagnosis for connective tissue diseases, and AVISE Lupus, which assesses complement system activation. The company's portfolio also includes AVISE APS for antiphospholipid syndrome, AVISE SLE Prognostic for risk assessment of complications, and tests for monitoring treatment efficacy in rheumatoid arthritis. Established in 2002 and headquartered in Vista, California, Exagen is dedicated to providing rheumatologists with timely and accurate diagnostic tools to enhance patient care.
AFT Pharmaceuticals
Debt Financing in 2014
AFT Pharmaceuticals Limited is a pharmaceutical company based in Auckland, New Zealand, that develops, licenses, and sells a diverse range of medical products. Established in 1997, the company offers approximately 130 prescription and non-prescription products, focusing on areas such as allergy relief, eye care, first aid, pain management, fungal treatments, and skin care, as well as dietary supplements. AFT Pharmaceuticals operates in multiple regions, including New Zealand, Australia, Southeast Asia, and other international markets, with a significant portion of its revenue generated from Australia. The company is also engaged in the distribution of pharmaceuticals, enhancing its presence in the healthcare sector through innovation and product development.
NanoString Technologies
Post in 2014
NanoString Technologies, Inc. is a provider of life science tools focused on translational research and molecular diagnostics, headquartered in Seattle, Washington. Established in 2003, the company utilizes a unique digital molecular barcoding technology to create a range of products that facilitate gene expression analysis, microRNA studies, and copy number variation detection. Key offerings include the nCounter Analysis System, which consists of the nCounter MAX and FLEX systems, and the nCounter SPRINT Profiler, all designed for automated sample processing and data collection. The nSolver Analysis Software aids researchers in data normalization and analysis. Additionally, NanoString provides various custom CodeSets and panels tailored for specific applications, including cancer profiling and autoimmune disease research. The company is advancing the field of spatial genomics with its GeoMx Digital Spatial Profiler system and is developing the Hyb & Seq molecular profiling system for gene sequence analysis. NanoString collaborates with several pharmaceutical companies and research institutions to enhance its product offerings and expand its impact in the scientific community.
Biodesix
Debt Financing in 2014
Biodesix, Inc. is a diagnostic solutions company based in Boulder, Colorado, specializing in blood-based tests for lung cancer and related services. The company offers a range of diagnostic tests, including the Nodify XL2 and Nodify CDT tests, which assist physicians in assessing the risk of malignancy in patients with suspicious lung nodules. Additionally, Biodesix provides tumor profiling and immune profiling tests, such as GeneStrat and VeriStrat, to support timely treatment decisions for oncologists. These tests are processed in a CLIA-certified laboratory, with results typically available within 72 hours. Beyond its diagnostic offerings, Biodesix also engages in clinical research, development, and testing services for biopharmaceutical companies, focusing on the development and commercialization of companion diagnostics to enhance therapeutic efficacy. Established in 2005, Biodesix continues to advance its proprietary mass spectrometry-based discovery platform to improve patient outcomes in lung disease.
Solta Medical
Post in 2013
Solta Medical, Inc. is a medical device company specializing in energy-based systems for aesthetic applications. Founded in 1995 and headquartered in Hayward, California, the company designs, develops, and manufactures a range of products for skin rejuvenation and body contouring. Notable offerings include the Thermage NXT system, which provides non-invasive skin tightening and cellulite enhancement, as well as the Fraxel re:fine, re:store, and re:pair systems, which address various skin conditions such as fine lines, pigmentation, acne scars, and deeper wrinkles. These systems comprise handpieces, a user-friendly console, an energy source, and disposable treatment tips. Solta Medical serves a diverse clientele, including dermatologists, plastic surgeons, and gynecologists, and distributes its products through a direct sales force and a network of distributors both in the United States and internationally. The company was previously known as Thermage, Inc. before rebranding to Solta Medical in January 2009.
Exagen
Debt Financing in 2013
Exagen Inc. is a diagnostics company focused on improving the care of patients with autoimmune diseases through the development and commercialization of innovative testing products under its AVISE brand. Utilizing its proprietary Cell-Bound Complement Activation Products technology, Exagen offers a range of tests aimed at the diagnosis, prognosis, and monitoring of complex autoimmune and autoimmune-related disorders, such as systemic lupus erythematosus and rheumatoid arthritis. Among its key products are AVISE CTD, which supports differential diagnosis for connective tissue diseases, and AVISE Lupus, which assesses complement system activation. The company's portfolio also includes AVISE APS for antiphospholipid syndrome, AVISE SLE Prognostic for risk assessment of complications, and tests for monitoring treatment efficacy in rheumatoid arthritis. Established in 2002 and headquartered in Vista, California, Exagen is dedicated to providing rheumatologists with timely and accurate diagnostic tools to enhance patient care.
Exagen Inc. is a diagnostics company focused on improving the care of patients with autoimmune diseases through the development and commercialization of innovative testing products under its AVISE brand. Utilizing its proprietary Cell-Bound Complement Activation Products technology, Exagen offers a range of tests aimed at the diagnosis, prognosis, and monitoring of complex autoimmune and autoimmune-related disorders, such as systemic lupus erythematosus and rheumatoid arthritis. Among its key products are AVISE CTD, which supports differential diagnosis for connective tissue diseases, and AVISE Lupus, which assesses complement system activation. The company's portfolio also includes AVISE APS for antiphospholipid syndrome, AVISE SLE Prognostic for risk assessment of complications, and tests for monitoring treatment efficacy in rheumatoid arthritis. Established in 2002 and headquartered in Vista, California, Exagen is dedicated to providing rheumatologists with timely and accurate diagnostic tools to enhance patient care.
RainDance Technologies
Debt Financing in 2013
RainDance Technologies, based in Billerica, Massachusetts, specializes in developing genomic tools for non-invasive liquid biopsy applications focused on the research, early detection, and treatment of cancer, as well as other inherited and infectious diseases. The company offers a range of innovative products, including the RainDrop digital polymerase chain reaction platform, which utilizes picoliter-sized droplets for multiplex detection of various genetic materials. Additionally, RainDance provides the ThunderStorm automated next-generation sequencing content enrichment solution, and the ThunderBolts NGS panels, designed for profiling significant cancer mutations and targeting genes associated with myeloid disorders. Through its advanced droplet technology, RainDance enables research institutions and laboratories to conduct precise genetic analysis, facilitating the understanding of complex genetic variations. Founded in 2004, the company operates as a subsidiary of Bio-Rad Laboratories and serves a global market through sales representatives and distributors.
Valeritas Holdings
Debt Financing in 2013
Valeritas Holdings, Inc. was a medical technology company focused on developing and commercializing innovative solutions for the treatment of Type 2 diabetes. Founded in 2006 and headquartered in Bridgewater, New Jersey, the company offered the V-Go, a wearable insulin delivery device designed for basal-bolus therapy, allowing patients to manage their insulin intake conveniently and discreetly. Valeritas was also working on additional products, including the V-Go Prefill, aimed at simplifying the device-filling process, and V-Go SIM, which would facilitate real-time tracking of dosing utilization. The company marketed its products through third-party wholesalers and medical supply distributors, aiming to enhance the health and quality of life for individuals living with diabetes. However, on June 30, 2020, Valeritas Holdings filed for Chapter 11 bankruptcy, leading to its cessation of operations.
Good Start Genetics
Debt Financing in 2013
Good Start Genetics, Inc. is a molecular diagnostics company based in Cambridge, Massachusetts, focused on genetic screening for inherited diseases. Founded in 2007, the company aims to transform reproductive medicine by providing physicians and patients with actionable insights into inherited genetic disorders. Good Start Genetics offers a range of services, including EmbryVu, a preimplantation genetic screening test designed to enhance in vitro fertilization outcomes by identifying suitable embryos for implantation. The company employs advanced next-generation DNA sequencing technology, along with other established genetic screening methods, to deliver high carrier detection rates. Additionally, through its GoodStart Select program, it provides a comprehensive menu of genetic carrier screening tests for both known and novel mutations, all supported by a commitment to customer care and genetic counseling. As of August 2017, Good Start Genetics operates as a subsidiary of Invitae Corporation.
TriVascular
Debt Financing in 2013
TriVascular Technologies, Inc. is a medical device company focused on developing and commercializing technologies for the minimally invasive treatment of abdominal aortic aneurysms (AAA) and thoracic aortic conditions. The company is known for its Ovation System, which includes a stent graft platform designed for endovascular aortic repair. Key components of the Ovation System feature an aortic body, iliac limbs, and polymer fill, which contribute to its effectiveness in treating AAA. TriVascular markets its products through direct sales in the United States and several European countries, as well as via distributors in other regions. Founded in 2007 and headquartered in Santa Rosa, California, TriVascular has been recognized for its innovative approach to addressing unmet clinical needs in aortic disease treatment. The company operates as a subsidiary of Endologix Inc.
Tandem Diabetes Care
Debt Financing in 2013
Tandem Diabetes Care, Inc. is a medical device company headquartered in San Diego, California, which specializes in the design, development, and commercialization of insulin delivery systems for individuals with insulin-dependent diabetes. Its flagship product, the t:slim X2 insulin delivery system, includes a pump, a 300-unit disposable insulin cartridge, and an infusion set. The company offers advanced features such as Basal-IQ Technology and Control-IQ Technology, along with the Tandem Device Updater for software enhancements. Additionally, Tandem provides the t:connect web-based data management application and the Sugarmate mobile app to support diabetes management for users and their caregivers. Tandem Diabetes Care entered the insulin pump market in 2012 and has since expanded its product line, including the recent launch of the smaller Mobi pump and development of a tubeless pump. The majority of the company’s revenue is generated in the United States, with additional sales from other developed countries.
Corium International
Convertible Note in 2012
Corium International, Inc. is a biopharmaceutical company based in Menlo Park, California, that specializes in the development, manufacture, and commercialization of specialty pharmaceutical products utilizing transdermal and transmucosal delivery systems. The company offers a range of products, including the Clonidine Transdermal Delivery System for hypertension, Fentanyl TDS for chronic pain management, and Crest Whitestrips for teeth whitening. Corium's pipeline includes Twirla, a hormonal contraceptive patch; MicroCor hPTH(1-34) for severe osteoporosis; and transdermal systems for Alzheimer's treatment, among others. Additionally, the company is advancing projects for psychiatric disorders and Parkinson's disease. Corium collaborates with several pharmaceutical companies, enhancing its research and development capabilities. The firm is recognized for its proprietary delivery technologies that improve therapeutic outcomes and safety profiles across various therapeutic areas.
Bioniche Pharma Group
Debt Financing in 2012
Bioniche Pharma Group manufactures and markets sterile injectable pharmaceutical products.